All In Biotech

Drug Trial Radar · NCT04874233

Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers

A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2)

Last checked: Nov 19, 2026Latest source record: Mar 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

80

Actual

Start

Apr 19, 2021

Primary completion

Nov 30, 2021

Study completion Dec 15, 2021

Sponsor

Lead sponsor
Rivus Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
May 5, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase 2a, randomized, parallel-group, placebo-controlled, double-blind, repeated-dose study to evaluate the safety and efficacy of three oral dose levels of HU6 compared to placebo over the course of 61 days in subjects with high BMI and evidence of elevated liver fat.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • HU6Drug

    HU6 is active study drug

  • PlaceboDrug

    Non-active study drug N = 20

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Change From Baseline in Liver Fat Content as Assessed by MRI-PDFFTime frame: Baseline and 61 days;

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Prism Clinical Research

    Minneapolis, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.